India's NPPA caps trade margins on anti-cancer drugs to reduce costs significantly, aiming for annual savings of ₹2,500 crore ...
Samsung Bioepis has placed its Keytruda biosimilar SB27 into FDA review, backed by Phase 3 lung cancer equivalence data from ...
FDA set April 22, 2027, as the target action date for both applications; Merck will present Phase 3 subgroup and ...
Shares of gene editing therapy companies mostly surged this past week on two growth catalysts: Data readouts at the European Society of Gene and Cell Therapy’s 33rd ESGCT Annual Congress, and the ...
According to Merck, Keytruda's key patent protection is set to expire in 2028 in the United States and China, followed by ...
Price reductions have been seen in drugs that are used to treat different cancers. However, the price cuts have not been uniform. Several expensive medicines have remained unchanged. This raises an ...
In a crucial regulatory update for healthcare providers and oncology patients across the country, the revised maximum retail ...
The revised maximum retail price (MRP) list of non-scheduled anti-cancer drugs, effective from November 9, 2026, shows no change in the prices of ...
12d
Patented, single source cancer drug prices remain unchanged under 30% margin cap, NPPA data shows
NPPA data show most single-source cancer drug prices remained unchanged under a 30% trade-margin cap, questioning the measure ...
India's drug price regulator, the National Pharmaceutical Pricing Authority (NPPA), has significantly reduced the maximum ...
The National Pharmaceutical Pricing Authority (NPPA) has revised the maximum retail prices (MRPs) of 543 cancer drug brands ...
The National Pharmaceutical Pricing Authority (NPPA) has published updated lists of company-reported maximum retail prices ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results